Exploring the characteristics of the SKP2-CDK6 axis in pancreatic cancer cell metastasis and its clinical significance
The SKP2-CDK6 axis may drive PDAC progression and chemoresistance. Co-targeting SKP2 and CDK6 in combination with gemcitabine may represent a promising therapeutic approach, warranting further preclinical and clinical evaluation to improve outcomes for patients with PDAC.
Authors
- Tzu-Yi Chen (ORCID: https://orcid.org/0009-0005-9332-709X)
- Chiao-Ying Lai
- Moi Sin-Hua
- Chun‐Chieh Wu (ORCID: https://orcid.org/0000-0001-8726-3302)
- Yi-Zi Chen
- Yu-Hsuan Hung
- Hui-Ching Wang
- Mei-Ren Pan
- Shu-Jyuan Chang
- Li-Tzong Chen
- Chi-Wen Luo
- Yu-Ci Yang
- Ya-Hui Chang
Institutions
- Kaohsiung Medical University (TW)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
Publication Details
- Journal
- Experimental and Molecular Pathology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1016/j.yexmp.2026.105024
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00